Third Quarter 2026 Highlights. Achieved quarterly net sales of $536 million, a 15% GAAP increase and a 6% organic increase year-over-year; Generated GAAP operating income of $88 m ...

Teva Pharmaceutical Industries Ltd. ( TEVA ), On Monday, announced that it will discontinue the Phase 2 TOPAS-MSA study evaluating emrusolmin (TEV-'286) in adults with multiple system atrophy (MSA).

Teva Pharmaceutical Industries is discontinuing its Phase 2 TOPAS-MSA trial of emrusolmin (TEV-'286) after an independent data monitoring ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. TEVA, will discontinue its Phase 2 TOPAS-MSA ...

Teva Pharma Industries Ltd ADRs (NYSE:TEVA) declined over 3% in premarket trading Monday after the company announced it will discontinue its Phase 2 TOPAS-MSA study of emrusolmin (TEV-'286) following ...

Emrusolmin is being developed in partnership with MODAG GmbH. Teva said the decision concerns TOPAS-MSA and does not represent a final decision on the broader emrusolmin program. In pre-market trading ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries ( TEVA ), said it will discontinue its Phase 2 TOPAS-MSA study evaluating emrusolmin (TEV-‘286) in adults with multiple system ...

Pharmaceuticals, a U.S. affiliate of Teva, announced that it will discontinue the Phase 2 TOPAS-MSA study evaluating ...

Teva will stop its Phase 2 TOPAS-MSA trial of emrusolmin after an interim analysis found a low likelihood of meeting the primary efficacy goal; no safety concerns were identified. The company said the ...

Predictive Interim analysis indicates low probability of study meeting its primary efficacy endpoint if ...

Picture a son who has worked his father’s farm since he was a teenager. Dad spent his last years in long-term care, Medicaid ...

Good evening, I'm Minori Asahina! MSA (Misawa SI Agent) is a company where the president and all employees are AI. Today, ...